|
1
|
Besses C, Cervantes F, Pereira A, Florensa
L, Solé F, Hernández-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman
C and Montserrat E: Major vascular complications in essential
thrombocythemia: a study of the predictive factors in a series of
148 patients. Leukemia. 13:150–154. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weng S, Zhu X, Jin Y, Wang T and Huang H:
Protective effect of erythropoietin on myocardial infarction in
rats by inhibition of caspase-12 expression. Exp Ther Med.
2:833–836. 2011.PubMed/NCBI
|
|
3
|
Schafer AI: Thrombocytosis. N Engl J Med.
350:1211–1219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mizuta E, Takeda S, Sasaki N, Miake J,
Hamada T, Shimoyama M, Tajima F, Igawa O, Shigemasa C and Hisatome
I: Acute myocardial infarction in a patient with essential
thrombocythemia: successful treatment with percutaneous
transluminal coronary recanalization. Circ J. 69:1000–1002. 2005.
View Article : Google Scholar
|
|
5
|
Pick RA, Glover MU, Nanfro JJ, Dubbs WF,
Gibbons JA and Vieweg WV: Acute myocardial infarction with
essential thrombocythemia in a young man. Am Heart J. 106:406–407.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Z, Wan X, Liu Y, Lin X, Ni Z, Yang X
and Zhang L: Non-ST-segment elevation myocardial infarction in a
patient with essential thrombocythemia treated with glycoprotein
IIb/IIIa inhibitor: a case report. Clin Appl Thromb Hemost.
17:532–534. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johansson P: Epidemiology of the
myeloproliferative disorders polycythemia vera and essential
thrombocythemia. Semin Thromb Hemost. 32:171–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McIntyre KJ, Hoagland HC, Silverstein MN
and Petitt RM: Essential thrombocythemia in young adults. Mayo Clin
Proc. 66:149–154. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rossi C, Randi ML, Zerbinati P, Rinaldi V
and Girolami A: Acute coronary disease in essential thrombocythemia
and polycythemia vera. J Intern Med. 244:49–53. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alvarez-Larrán A, Cervantes F, Bellosillo
B, Giralt M, Juliá A, Hernández-Boluda JC, Bosch A, Hernández-Nieto
L, Clapés V, Burgaleta C, Salvador C, Arellano-Rodrigo E, Colomer D
and Besses C: Essential thrombocythemia in young individuals:
frequency and risk factors for vascular events and evolution to
myelofibrosis in 126 patients. Leukemia. 21:1218–1223. 2007.
|
|
11
|
Carobbio A, Finazzi G, Guerini V, Spinelli
O, Delaini F, Marchioli R, Borrelli G, Rambaldi A and Barbui T:
Leukocytosis is a risk factor for thrombosis in essential
thrombocythemia: interaction with treatment, standard risk factors,
and Jak2 mutation status. Blood. 109:2310–2313. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Zhang ZZ, Wu Y, Zhan J, He XH and
Wang YL: Honokiol protects rat hearts against myocardial ischemia
reperfusion injury by reducing oxidative stress and inflammation.
Exp Ther Med. 5:315–319. 2013.PubMed/NCBI
|
|
13
|
Wolanskyj AP, Schwager SM, McClure RF,
Larson DR and Tefferi A: Essential thrombocythemia beyond the first
decade: life expectancy, long-term complication rates, and
prognostic factors. Mayo Clin Proc. 81:159–166. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ruggeri M, Rodeghiero F, Tosetto A,
Castaman G, Scognamiglio F, Finazzi G, Delaini F, Micò C, Vannucchi
AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A,
Mazzucconi MG, Santoro C and Barbui T; Gruppo Italiano Malattie
Ematologiche dell’Adulto (GIMEMA) CHronis Myeloproliferative
Diseases Working Party. Postsurgery outcomes in patients with
polycythemia vera and essential thrombocythemia: a retrospective
survey. Blood. 111:666–671. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Das SS, Bose S, Chatterjee S, Parida AK
and Pradhan SK: Thrombocytapheresis: managing essential
thrombocythemia in a surgical patient. Ann Thorac Surg. 92:e5–e6.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin D, Wu Y, Zhao L, Guo J, Zhang K and
Chen Z: Atorvastatin reduces serum HMGB1 levels in patients with
hyperlipidemia. Exp Ther Med. 4:1124–1126. 2012.PubMed/NCBI
|
|
17
|
Ohto T, Shihara H, Miyauchi Y and Nakajima
N: A case of coronary artery bypass surgery using left internal
thoracic artery and right gastroepiploic artery for a patient with
essential thrombocythemia. Jpn J Thorac Cardiovasc Surg.
46:767–771. 1998.(In Japanese).
|
|
18
|
Lv H and Ning B: Pathogenesis of
bloodstream infection in children with blood cancer. Exp Ther Med.
5:201–204. 2013.PubMed/NCBI
|
|
19
|
Harrison CN, Campbell PJ, Buck G, Wheatley
K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT,
Grigg AP, Revell P, Woodcock BE and Green AR; United Kingdon
Medical Research Council Primary Thrombocythemia 1 Study.
Hydroxyurea compared with anagrelide in high-risk essential
thrombocythemia. N Engl J Med. 353:33–45. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vannucchi AM, Guglielmelli P and Tefferi
A: Advances in understanding and management of myeloproliferative
neoplasms. CA Cancer J Clin. 59:171–191. 2009. View Article : Google Scholar : PubMed/NCBI
|
